Search for: "John Doe 1 " Results 8641 - 8660 of 12,912
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
4 Mar 2010, 10:44 pm by Jeffrey Richardson
  Click here for Documents to Go Premium ($14.99):  Fortune just released their annual list of the world's most admired companies, and Apple is #1 in 2010. [read post]
28 Sep 2023, 7:26 am by Peter J. Louie, Esq.
However, just because you have been charged with Driving Under the Influence does not mean you will be convicted. [read post]
14 May 2024, 7:15 am by Bryan Caplan
If even 1% were privatized over the next decade, I'd be amazed. [read post]
15 Sep 2016, 6:00 am by Jonathan Bailey
YouTube currently does use such technology but there are fears that smaller and newer sites might not have the resources needed to comply. [read post]
4 Oct 2010, 7:36 pm by Kevin Funnell
In a $14 trillion economy, $50 billion is less than 1% of economic output. [read post]
2 May 2012, 8:53 am by Joe Consumer
IOM concludes, “the FDA’s current approach to drug oversight in the postmarket setting is not sufficiently systematic and does not ensure that it assesses the benefits and risks of drugs consistently over the drug’s life cycle. [read post]
25 Sep 2012, 8:00 am by Trent Dykes
  Does your company have non-disclosure agreements with all necessary employees? [read post]
8 Mar 2012, 8:00 am by David Bernstein
  Think about John Kerry coming into Republican Senator Heinz’s fortune via Theresa, and you can see the potential problem. [read post]
17 Aug 2012, 10:01 pm by Colin Murray
Not Yet… (1)August 17, 2012 -- Floundering attempts at peace in Syria (0) [read post]
12 Oct 2016, 11:42 am by Steve Vladeck
(Rule 32(j)(1)(B) of the Federal Rules of Criminal Procedure requires the court to “advise the defendant of any right to appeal the sentence. [read post]
17 Jun 2018, 1:39 pm by Nikki Siesel
See Swiss Grill Ltd., John Hartwig, Christopher Hartwig and Mathhew Hartwih v. [read post]
2 May 2012, 8:53 am by Joe Consumer
IOM concludes, “the FDA’s current approach to drug oversight in the postmarket setting is not sufficiently systematic and does not ensure that it assesses the benefits and risks of drugs consistently over the drug’s life cycle. [read post]